Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy

Annals of Oncology

Volumn 9, Issue 7, 1998, Pages 739-744

  Postma, T J ^a   Heimans, J J ^a   Muller, M J ^b   Ossenkoppele, G J ^a   Vermorken, J B ^a,c   Aaronson, N K ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemotherapy; Grading; Peripheral neurotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; NEUROPATHY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RATING SCALE;

EID: 0031823939     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008344507482     Document Type: Article

References (22)

1. Vietli TJ. Evaluation of toxicity: Clinical issues. Cancer Treat Rep 1980; 64: 457-61.
2. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
3. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
4. Castellanos AM, Fields WS. Grading of neurotoxicity in cancer therapy. J Clin Oncol 1986; 4: 1277-8
5. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
6. Vantongelen K. A Practical Guide to EORTC Studies. Brussels: EORTC Central Office-Data Center 1994.
7. Dyck PJ, Karnes J, O'Brien PC, Zimmerman IR. Detection thresholds of cutaneous sensation in humans. In Dyck PJ, Thomas PK, Lambert EH. Bunge R (eds): Peripheral Neuropathy. Vol 1, second editon. Philadelphia: WB Saunders Company 1984; 1103-38.
8. Edwards RHT, Wiles CM, Mills KR. Quantitation of muscle contraction and strength. In Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds): Peripheral Neuropathy. Vol 1, second edition. Philadelphia: WB Saunders Company 1984; 1093-102.
9. Stam J. The tendon reflexes. A clinical and electromyographic study. Thesis, University of Amsterdam 1987.
10. Lee J, Koh D, Ong CN. Statistical evaluation of agreement between two methods for measuring a quantitative variable. Comput Biol Med 1989; 19: 61-70.
11. Fleiss JL. The equivalence of weighted Kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas 1973; 33: 613-9.
12. Landis JR, Koch CG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 174.
13. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale. NJ: Lawrence Erlbaum Associates 1988.
14. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12.
15. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve Growth Factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 87-90.
16. Smyth JF, Bowman A, Perren T et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial. Ann Oncol 1997; 8: 569-73.
17. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85: 1138-48.
18. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229-39.
19. De Angelis LM, Gnecco C, Taylor L, Warrell RP. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer 1991; 67: 2241-6.
20. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96: 69-86.
21. Sprangers MAG, Cull A, Bjordal K et al. The European Organization for Research and Treatment of Cancer approach to quality of life assessment: Guidelines for developing questionnaire modules. Qual Life Res 1993; 2: 287-95.
22. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.